Application of stachyose in preparation of medicine for treating castration-resistant prostate cancer

A castration-resistant, prostate cancer technology, applied in the field of biomedicine, can solve problems such as drug resistance of CRPC, and achieve the effect of shortening the time, time cost and economic cost of clinical transformation.

Active Publication Date: 2021-09-28
JIANGNAN UNIV
View PDF5 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, whether it is EPI or Enza, the treatment of CRPC will generally produce drug resistance in about 18 months

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of stachyose in preparation of medicine for treating castration-resistant prostate cancer
  • Application of stachyose in preparation of medicine for treating castration-resistant prostate cancer
  • Application of stachyose in preparation of medicine for treating castration-resistant prostate cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0029] Example 1 The process of using EPI and Enza to produce DTP / DTEP in prostate cancer LNCaP cells and the characteristics of this model

[0030] Prostate cancer L-DTP cell lines resistant to EPI and Enza L-DTP-EPI and L-DTP-Enza can inhibit the protein expression of AR and its targets, and the cell growth inhibition is manifested by cycle arrest in G0 / G1 phase.

[0031] 1. Experimental method:

[0032] LNCaP cells 1x10 6 Each species was planted in a 10cm cell culture dish, and after adhering to the wall on the second day, they were treated with EPI and Enza respectively for 9 days. During this period, fresh drug-containing medium was cultured every three days, and a part of the cells (that is, DTP cells) were collected after 9 days for subsequent use. For the test, the rest continued to be treated with drugs, during which they were cultured with fresh drug-containing medium every three days, and collected after 33 days (ie, DTEP cells) for subsequent tests. After genera...

Embodiment 2

[0035] Example 2 The in vitro effect of EPI, Enza and Stac drug combination respectively

[0036] Further, CCK8 was used alone and in combination in drug-resistant L-DTP cells to illustrate the in vitro anti-tumor effect of Stac drugs in drug-resistant L-DTP (EPI) and L-DTP (Enza) cells.

[0037] 1. Experimental method

[0038] After seeding drug-resistant cells L-DTP (including L-DTP (EPI) and L-DTP (Enza)) in a 96-well plate to adhere to the wall, a series of concentrations of Stac drugs from high to low were prepared to find the optimal concentration. The best drug concentration of Stac, and then use this concentration to determine single use (L-DTP(EPI)-Stac), combined use [L-DTP(EPI)-combination(EPI+Stac)], [L-DTP(Enza)- combination(Enza+Stac)】respectively in the survival rate of drug-resistant cells L-DTP. Finally, the CI value was calculated in L-DTP cells using Calcusyn software.

[0039] 2. The result is as follows Figure 4 as shown, Figure 4 middle, Figure 4...

Embodiment 3

[0041] Example 3 The effect of the combined drug regimen of Enza and Stac on the C-MYC overexpression prostate cancer mouse model after continuous drug Enza resistance

[0042] Further, in the prostate cancer mouse model, the effect of combined administration of Enza and Stac on relapsed mice after chemical castration (ie continuous administration of Enza) was illustrated.

[0043] 1. Experimental method

[0044] Construct a spontaneous prostate cancer mouse model with C-MYC (Hi-Myc) overexpression. At 4 months, the mice developed mPIN / Cancer transition. At this time, the mice were randomly divided into NC control group (gavage solution), Enza drug After that, Enza was administrated once every three days, and Enza was 10mg / Kg for a total of 30 days. Afterwards, some mice were neck-broken and their prostate cancer was taken to take pictures and weighed. It was found that Enza could significantly alleviate the symptoms. The NC control group was reduced by half, and the remainin...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses application of stachyose in preparation of a medicine for treating castration-resistant prostate cancer, and belongs to the technical field of biological medicine. The application of stachyose provides a new strategy for preparing the medicine for treating the CRPC by combining the stachyose with an androgen receptor antagonist for the first time, and multi-angle and multi-level verification research is carried out. A stachyose and androgen receptor combined pharmaceutical composition can be used for treating the castration-resistant prostate cancer, the effect of enzalutamide on inhibiting the castration-resistant prostate cancer is remarkably improved, a natural compound is applied to the advanced stage of the cancer, and the pharmaceutical composition has important clinical treatment significance.

Description

technical field [0001] The invention belongs to the technical field of biomedicine. It specifically relates to the application of stachyose in the preparation of drugs for treating castration-resistant prostate cancer. Background technique [0002] Androgen deprivation therapy is the standard treatment for advanced prostate cancer, but patients will eventually develop castration-resistant prostate cancer (CRPC) after an average of 1-3 years of treatment. The so-called CRPC refers to prostate cancer that still progresses after initial continuous androgen deprivation therapy (ADT). Since docetaxel was proved to prolong the overall survival of patients with metastatic castration-resistant prostate cancer (mCRPC) in 2004, abiraterone acetate, enzalutamide, Drugs targeting the disease stage of mCRPC, such as cabazitaxel, have changed the current treatment status of these patients, but in the end, it is difficult to completely reverse CRPC. Therefore, finding other effective th...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/702A61K45/06A61P35/00
CPCA61K31/702A61K45/06A61P35/00
Inventor 陈永泉王荣许璐王小英朱升龙
Owner JIANGNAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap